Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …

Brain imaging techniques using PET improve our understanding of the different AD-related
pathologies and their relationship with each other along the course of disease. With more …

Alzheimer's disease (AD) is the main cause of dementia, with its diagnosis and management
remaining challenging. Amyloid positron emission tomography (PET) has become …

Purpose Amyloid positron emission tomography (PET) with [18F] florbetaben (FBB) is an
established tool for detecting Aβ deposition in the brain in vivo based on visual assessment …

Background: We previously introduced a machine learning-based Alzheimer's Disease
Designation (MAD) framework for identifying AD-related metabolic patterns among …

We acquired brain 18F-FDG and 18F-flutemetamol PET images using a time-of-flight system
dedicated to the head (dhPET) and a conventional whole-body PET/CT (wbPET) system and …

Introduction Centiloid (CL) scaling has become a standard quantitative measure in amyloid
PET because it allows the direct comparison of results across sites, even when different …

Rationale Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in
Alzheimer's disease pathogenesis. In clinical practice, trained readers will visually …

Propose This study aims to explore the use of the Centiloid (CL) method in amyloid-β PET
quantification to evaluate distinct cognitive aging stages, investigating subjects' mismatch …

Several programs are widely used for clinical and research purposes to automatically
quantify the degree of amyloid deposition in the brain using positron emission tomography …